title: [Therapeutic impact of alpha interferon in chronic myelogenous leukaemia].
abstract: BACKGROUND
  Ten years after the use of alpha interferon in chronic myelogenous (CML) leukaemia treatment, we review this treatment.
  
  
  OBJECTIVE
  We propose through this study to evaluate the therapeutic answer of the patients reached of CML in chronic phase and to study its impact on survival.
  
  
  METHODS
  To be done we carried out a descriptive and analytical retrospective study concerning 40 patients carrying Chronic Myelogenous Leukaemia.
  
  
  RESULTS
  The average age was 39.05 years and ratio sex was 0.9. 60% of the patients profited from the arm Hydroxyurea + Interferon alpha + Cytosine Arabinoside and 40% from Hydroxyurea + Interferon. The complete haematological answer was observed in 85.5%. The cytogenetic answer was documented only for two cases, and it acted of complete answer. On the evolutionary level, it was noted 27.5% of deaths related to a blastic transformation. The side effects were marked by occurred of alopecia, herpes and the gripal syndrome. The median of survival observed was 68.233 months or 5.68 years. The age, socioeconomic level, delay of treatment started, therapeutic protocol, length and regularity of treatment influenced the therapeutic response.
  
  
  CONCLUSIONS
  Many factors influence the treatment response.
authors: CHU de Yopougon. tolo_aissata@yahoo.fr
authors: A
authors: A
authors: Tolo-Diebkilé
authors: K G
authors: KG
authors: Koffi
authors: G D
authors: GD
authors: Sawadogo
authors: F S D
authors: FS
authors: Ndiaye
authors: D C
authors: DC
authors: Nanho
authors: Y M
authors: YM
authors: Sékongo
authors: B
authors: B
authors: Kouakou
authors: N
authors: N
authors: Méité
authors: R
authors: R
authors: Ayemou
authors: I
authors: I
authors: Sanogo
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001752:Blast Crisis / Q000209:etiology; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000097:blood; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects; D053208:Kaplan-Meier Estimate; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D012189:Retrospective Studies; D012959:Socioeconomic Factors; D014775:Virus Activation; D055815:Young Adult
chemical_list: D007155:Immunologic Factors; D016898:Interferon-alpha; D003561:Cytarabine; D016044:Fusion Proteins, bcr-abl; D006918:Hydroxyurea